- Sponsored Content
- Manufacturing
The “early health” Vision
BPI Contributor
January 1, 2013
1 Min Read
Sponsored Content
New approaches to vaccine production are needed. GE Healthcare Life Sciences contributes to the “early health” vision by supporting advances in vaccine development through innovative manufacturing solutions that help to shorten time-to-market, increase output, and assure quality.
About the Author(s)
You May Also Like
Upcoming Webcasts
Insider News
Bioprocess industry eyes China's stimulus program amid funding woes
May 1, 2024|2 Min ReadBIOSECURE and Catalent deal could bag more biz for Thermo
April 29, 2024|3 Min ReadPfizer wins approval for $3.5m hemophilia B gene therapy
April 29, 2024|1 Min ReadMultiply and Stanford Labs look to bring automation to CGTs
April 29, 2024|5 Min Read
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More